FV Leiden mutation and deep venous thrombosis in Vojvodina: A case-control study

• Main Authors: Salatić Iva, Kiralj Katarina, Mitić Gorana, Veselinović Igor, Vapa Dušan
• Format: Article
• Language: English
• Published: Society of Medical Biochemists of Serbia, Belgrade 2011-01-01
• Series: Journal of Medical Biochemistry
• Subjects: factor v leiden; deep vein thrombosis
• Online Access: https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2011/1452-82581101051S.pdf
• ISSN: 1452-8258; 1452-8266

Between September 2007 and February 2010, the occurrence of symptomatic deep venous thrombosis (DVT) was investigated in a cohort of 79 consecutive patients. A case-control study included 71 healthy controls matched with cases for sex and age. The prevalence of factor V G1691A mutation genotype was analyzed. Eighteen cases (22.79%; 95% confidence interval (CI) 13.53% to 32.03%) and four controls (5.63%; 95% CI 0.27% to 10.99%) were heterozygous carriers of FV Leiden (p= 0.025). The odds ratio for DVT was 4.94 (95% CI 1.58 to 15.42) and the relative risk 4.04 (95% CI 1.44-11.38) compared with FV 1691G carriers. Four cases were homozygous carriers of FV Leiden, giving a prevalence of 5.06% (95% CI 0.23 to 9.89%) and no controls, therefore OR and RR calculation was based on the prevalence of homozygotes in the general Caucasian population. The OR for DVT was 47.28 (95% CI 0.04 - 52167.3) and the RR 45.57 (95% CI 0.04 to 49540.77; p=0.025) compared with FV 1691 G carriers. Our study confirms that factor V Leiden carriers in Vojvodina, as in similar studies previously carried out in other populations, have an increased risk of developing DVT. The evaluated risk of DVT in heterozygous carriers of the mutation is four to five-fold higher, whereas for homozygous carriers it is 45- to 48-fold higher than in non-carriers. These results confirm that patients with DVT and their relatives should undergo screening for FV Leiden mutation. .